title: Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab.
authors.affiliation: Unit of Dermatology, University of Padua, Padua, Italy.
authors.forename: Irene
authors.initials: I
authors.lastname: Russo
authors.affiliation: Unit of Dermatology, University of Padua, Padua, Italy.
authors.forename: Giorgia
authors.initials: G
authors.lastname: Sacco
authors.affiliation: Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Frega
authors.affiliation: Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Polo
authors.affiliation: Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Pasello
authors.affiliation: Unit of Dermatology, University of Padua, Padua, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Alaibac
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000077192:Adenocarcinoma of Lung; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C000594389:atezolizumab